Table_3_Prevalence of sarcopenia in patients with COPD through different musculature measurements: An updated meta-analysis and meta-regression.docx

AimChronic obstructive pulmonary disease (COPD) patients vary widely in terms of the prevalence of sarcopenia, which is partially attributed to differences in diagnostic criteria and disease severity. There are several different musculature measurements that are used to quantify sarcopenia. This study included published literature for meta-analysis to assess the sarcopenia prevalence in COPD patients and correlate the disease with the clinical characteristics of such patients.
MethodsA comprehensive review of the English and Chinese literature on sarcopenia prevalence in COPD patients was conducted using electronic databases such as China National Knowledge Infrastructure (CNKI), Web of Science, Cochrane Library, EMBASE, PubMed, and Wanfang. Two researchers analyzed the studies for Newcastle-Ottawa Scale. The software Stata 11.0 was employed for the analysis of the acquired data. The standard mean differences method was utilized for the estimation and quantification of the effect size. Furthermore, a fixed- or random-effects model was employed for conducting a combined analysis.
ResultsIn total, 56 studies were included as per the specific inclusion criteria. The resulting data of the assessed COPD patients in this research indicated a 27% prevalence of sarcopenia. Further analysis of subgroups was executed per disease severity, ethnicity, diagnostic criteria, gender, and age. Per these findings, increased disease severity elevated the prevalence of sarcopenia. The Latin American and Caucasian populations indicated an increased prevalence of sarcopenia. In addition, the prevalence of sarcopenia was related to diagnostic criteria and definition. Male COPD patients had a higher prevalence of sarcopenia than female COPD patients. COPD patients with an average age greater than 65 had a slightly higher prevalence of sarcopenia. COPD patients with comorbid sarcopenia had poorer pulmonary function, activity tolerance, and clinical symptoms than patients with COPD alone.
ConclusionSarcopenia prevalence is high (27%) in COPD patients. In addition, these patients had worse pulmonary function and activity tolerance compared to patients without sarcopenia.
Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=367422, identifier CRD42022367422.

目的 慢性阻塞性肺疾病（Chronic Obstructive Pulmonary Disease, COPD）患者的肌肉减少症患病率差异显著，其部分成因与诊断标准及疾病严重程度的差异有关。目前临床存在多种用于量化肌肉减少症的肌肉量测量方法。本研究纳入已发表文献进行荟萃分析，旨在评估COPD患者的肌肉减少症患病率，并分析该病症与患者临床特征的关联。

方法 本研究通过中国知网（China National Knowledge Infrastructure, CNKI）、Web of Science、Cochrane图书馆、EMBASE、PubMed及万方数据等电子数据库，全面检索关于COPD患者肌肉减少症患病率的中英文文献。由2名研究者采用纽卡斯尔-渥太华量表（Newcastle-Ottawa Scale, NOS）对纳入研究进行质量评价。采用Stata 11.0软件对获取的数据进行统计分析，以标准均数差法对效应量进行估算与量化，并采用固定效应模型或随机效应模型进行合并分析。

结果 本研究共纳入符合特定纳入标准的56项研究。纳入的COPD患者数据显示，其肌肉减少症患病率为27%。本研究按疾病严重程度、种族、诊断标准、性别及年龄进行亚组分析，结果显示：疾病严重程度越高，肌肉减少症患病率越高；拉丁美洲人群与高加索人群的肌肉减少症患病率更高；肌肉减少症患病率与诊断标准及定义方式密切相关；男性COPD患者的肌肉减少症患病率高于女性患者；平均年龄大于65岁的COPD患者，其肌肉减少症患病率略高；合并肌肉减少症的COPD患者，其肺功能、活动耐量及临床症状均较单纯COPD患者更差。

结论 COPD患者的肌肉减少症患病率较高（27%）。此外，合并肌肉减少症的COPD患者，其肺功能与活动耐量均较无肌肉减少症的COPD患者更差。

系统评价注册信息：https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=367422，注册号为CRD42022367422。